Published in
American Society of Clinical Oncology, Journal of Clinical Oncology, 15_suppl(34), p. e15127-e15127
DOI: 10.1200/jco.2016.34.15_suppl.e15127
Links
Tools
Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study.
Journal article published in 2016 by
Federica Marmorino,
Chiara Cremolini,
Fotios Loupakis,
Cecilia Barbara,
Francesco Dargenio,
Emanuela Miraglio,
Gianluca Masi,
Lisa Salvatore 
,
Lorenzo Marcucci,
Lorenzo Antonuzzo,
Silvana Chiara,
Chiara Banzi,
Marta Schirripa,
Domenico Amoroso,
Andrea Bonetti
and other authors.
,
Lorenzo Marcucci,
Lorenzo Antonuzzo,
Silvana Chiara,
Chiara Banzi,
Marta Schirripa,
Domenico Amoroso,
Andrea Bonetti
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 